Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial

BACKGROUND: Group B streptococcus (GBS) is a major cause of invasive disease in young infants. Infants born to women with sufficient pre-existing anti-GBS capsular IgG antibodies are at reduced risk of GBS disease, making maternal immunisation a potential strategy for prevention. We aimed to assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Absalon, Judith, Segall, Nathan, Block, Stan L, Center, Kimberly J, Scully, Ingrid L, Giardina, Peter C, Peterson, James, Watson, Wendy J, Gruber, William C, Jansen, Kathrin U, Peng, Yahong, Munson, Samantha, Pavliakova, Danka, Scott, Daniel A, Anderson, Annaliesa S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760110/
https://www.ncbi.nlm.nih.gov/pubmed/32891191
http://dx.doi.org/10.1016/S1473-3099(20)30478-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760110/
https://www.ncbi.nlm.nih.gov/pubmed/32891191
http://dx.doi.org/10.1016/S1473-3099(20)30478-3

Ejemplares similares